Are COX-2 selective inhibitors safer than NSAIDs for patients with osteoarthritis and rheumatoid arthritis?

被引：0
|
作者：
Angel Lanas
机构：
[1] University Hospital,A Lanas is Clinical Chief of Gastroenterology and a Professor of Medicine in the Department of Gastroenterology
[2] Institute of Health Sciences of Aragon,undefined
[3] Zaragoza,undefined
[4] Spain.,undefined
来源：
Nature Clinical Practice Gastroenterology & Hepatology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：648 / 649
页数：1
相关论文
共 50 条
  • [21] The brand new selective COX-2 inhibitors NSAIDs.
    Cano, DL
    Rodríguez, BG
    Domínguez, YT
    Delgado, PH
    Esteban, JMH
    Gutiérrez, JMH
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1999, 91 (08) : 598 - 598
  • [22] Selective COX-2 inhibitors, NSAIDs, aspirin, myocardial infarction
    Dalen, JE
    ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (10) : 1091 - 1092
  • [23] Value of Information in the Osteoarthritis SettingCost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors
    Nicholas Latimer
    Joanne Lord
    Robert L. Grant
    Rachel O’Mahony
    John Dickson
    Philip G. Conaghan
    PharmacoEconomics, 2011, 29 : 225 - 237
  • [24] Selective COX-2 inhibitors may pose a greater risk of hyperkalaemia than nonselective NSAIDs
    Reactions Weekly, 2010, 1325 (1) : 6 - 6
  • [25] Risk of stroke in arthritis patients treated with cox-2 selective and non-selective NSAIDs
    Graham, David J.
    Singh, Gurkirpal
    Wang, H.
    Mannalithara, A.
    Lingala, V.
    Mithal, Alka
    Triadafilopoulos, George
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S67 - S67
  • [26] COX-2 Inhibitors in Patients with Sensitivity to Nonselective NSAIDs
    Cimbollek, Stefan
    Quiralte, Joaquin
    Avila, Robledo
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (22): : 2197 - 2198
  • [27] The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis
    Kamath, CC
    Kremers, HM
    Vanness, DJ
    O'Fallon, WM
    Cabanela, RL
    Gabriel, SE
    VALUE IN HEALTH, 2003, 6 (02) : 144 - 157
  • [28] NSAIDS, COX-2 INHIBITORS, AND THE GUT
    HAYLLAR, J
    BJARNASON, I
    LANCET, 1995, 346 (8974): : 521 - 522
  • [29] NSAIDS, COX-2 INHIBITORS, AND THE GUT
    BENNETT, A
    TAVARES, IA
    LANCET, 1995, 346 (8982): : 1105 - 1105
  • [30] NSAIDS, COX-2 INHIBITORS, AND THE GUT
    HAYLLAR, J
    BJARNASON, I
    LANCET, 1995, 346 (8990): : 1629 - 1629
12345